» Articles » PMID: 38890191

Stealth Nanocarriers in Cancer Therapy: a Comprehensive Review of Design, Functionality, and Clinical Applications

Abstract

Nanotechnology has significantly transformed cancer treatment by introducing innovative methods for delivering drugs effectively. This literature review provided an in-depth analysis of the role of nanocarriers in cancer therapy, with a particular focus on the critical concept of the 'stealth effect.' The stealth effect refers to the ability of nanocarriers to evade the immune system and overcome physiological barriers. The review investigated the design and composition of various nanocarriers, such as liposomes, micelles, and inorganic nanoparticles, highlighting the importance of surface modifications and functionalization. The complex interaction between the immune system, opsonization, phagocytosis, and the protein corona was examined to understand the stealth effect. The review carefully evaluated strategies to enhance the stealth effect, including surface coating with polymers, biomimetic camouflage, and targeting ligands. The in vivo behavior of stealth nanocarriers and their impact on pharmacokinetics, biodistribution, and toxicity were also systematically examined. Additionally, the review presented clinical applications, case studies of approved nanocarrier-based cancer therapies, and emerging formulations in clinical trials. Future directions and obstacles in the field, such as advancements in nanocarrier engineering, personalized nanomedicine, regulatory considerations, and ethical implications, were discussed in detail. The review concluded by summarizing key findings and emphasizing the transformative potential of stealth nanocarriers in revolutionizing cancer therapy. This review enhanced the comprehension of nanocarrier-based cancer therapies and their potential impact by providing insights into advanced studies, clinical applications, and regulatory considerations.

Citing Articles

Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities.

Rahman M, Jalouli M, Yadab M, Al-Zharani M Cancers (Basel). 2025; 17(4).

PMID: 40002294 PMC: 11852615. DOI: 10.3390/cancers17040701.


Emerging role of exosomes in cancer therapy: progress and challenges.

Li J, Wang J, Chen Z Mol Cancer. 2025; 24(1):13.

PMID: 39806451 PMC: 11727182. DOI: 10.1186/s12943-024-02215-4.

References
1.
Liu X, Reiss C . A Multifaceted Battle Against Cancer. Yale J Biol Med. 2015; 88(2):105-6. PMC: 4445431. View

2.
Cao J, Chen C, Wang Y, Chen X, Chen Z, Luo X . Influence of autologous dendritic cells on cytokine-induced killer cell proliferation, cell phenotype and antitumor activity . Oncol Lett. 2016; 12(3):2033-2037. PMC: 4998518. DOI: 10.3892/ol.2016.4839. View

3.
Gottesman M, Lavi O, Hall M, Gillet J . Toward a Better Understanding of the Complexity of Cancer Drug Resistance. Annu Rev Pharmacol Toxicol. 2015; 56:85-102. DOI: 10.1146/annurev-pharmtox-010715-103111. View

4.
He Z, Yue C, Chen X, Li X, Zhang L, Tan S . Integrative Analysis Identified CD38 As a Key Node That Correlates Highly with Immunophenotype, Chemoradiotherapy Resistance, And Prognosis of Head and Neck Cancer. J Cancer. 2023; 14(1):72-87. PMC: 9809333. DOI: 10.7150/jca.59730. View

5.
Liang W, Liu H, Zeng Z, Liang Z, Xie H, Li W . KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2-CXCL10 Axis in Colorectal Cancer. Cancer Immunol Res. 2023; 11(7):875-894. PMC: 10320689. DOI: 10.1158/2326-6066.CIR-22-0814. View